SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

"There is hope, including advances in early detection and treatment spearheaded by retina specialists that can help people ...

Six/UW/Seattle Children’s Cancer Consortium scientists received new funding from the Breast Cancer Research Foundation to ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

In 2025, children within the TEDDY study will submit their final samples at research clinics in Sweden, Finland, Germany and ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

SAN ANTONIO — Treatment with once-weekly semaglutide 2.4 mg (Wegovy ... in people with overweight/obesity and established cardiovascular disease (CVD). The new findings come from prespecified analyses ...

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. The loss of insulin leads to the ...

Doctors are currently using stem cells to treat a variety of medical conditions — and that list could soon become even larger ...